Dry Eye Drugs Market Scope
The dry eye drug market is expected to grow in the future due to the increased number of cases for dry eye disease results in the increased demand for its treatment. Additionally, factors such as aging, direct contact with dry wind or smoke and lack of vitamin A, etc increase the occurrence of the dry eye more likely which is boosting the demand for dry eye drugs. Further, market players are focusing on clinical trials for new drugs. For example, the FDA has accepted a new drug application for Kala Pharmaceuticals’ KPI-121 0.25% for the temporary relief of dry eye signs and symptoms.
The market study is being classified by Type (Artificial Tears and Anti-inflammatory Drugs), by Application (Hospital Pharmacies, Drug Stores and Online Pharmacies) and major geographies with country level break-up.
Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Dry Eye Drugs market throughout the predicted period.
Allergan plc (Ireland), Novartis International AG (Switzerland), Bausch Health Companies Inc. (Canada), Santen Pharmaceutical Co., Ltd. (Japan), Shire Plc (United States), Johnson & Johnson (United States), United Laboratories, Inc. (United States), Sun Pharmaceutical Industries Ltd. (India) and Senju Pharmaceutical Co. Ltd. (Japan) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Chongqing Jianfeng Industrial Group Co., Ltd (China) and Kala Pharmaceuticals (United States).
AdvanceMarketAnalytics has segmented the market of Global Dry Eye Drugs market by Type, Application and Region.
On the basis of geography, the market of Dry Eye Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
Market Leaders and their expansionary development strategies
In May 2019, Novartis announced that it has entered into an agreement with Takeda Pharmaceutical Company Limited to acquire the assets associated with Xiidra® (lifitegrast ophthalmic solution) 5% worldwide.
In Aug 2018, Sun Pharmaceutical Industries Ltd. announced that Sun Pharma has received approval for CEQUA (cyclosporine ophthalmic solution) 0.09%, from the U.S. Food and Drug Administration (FDA). CEQUA is indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye).
The FDA has accepted a new drug application for Kala Pharmaceuticals’ KPI-121 0.25% for the temporary relief of dry eye signs and symptoms, the company announced in a press release.
- Increasing Research and Development Activities from both Public and Private Research Organizations for New Drugs
- Increase in the Prevalence of Dry Eye Syndrome
- A Rising Awareness about Eye Care
- Increase in Awareness among the Population about Dry Eye Disease
- Potential Growth From Emerging Countries
- Increasing Number of Pipelines Studies and Drug Development
- Straight Government Regulation associated with Drug Production
- the Long Approval Process that For Approvement in any Drug
Key Target Audience
Dry Eye Drugs Manufacturers, Dry Eye Drugs Distributors/Traders/Wholesalers, Dry Eye Drugs Subcomponent Manufacturers, Industry Association, Healthcare Industry, Potential Investors, Research and Development Firm and Downstream Vendors
Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase